Stevenson, J. P., DeMaria, D., Sludden, J., Kaye, S. B., Paz-Ares, L., Grochow, L. B., ...
Background: Preclinical results support a prolonged schedule of administration for topoisomerase I inhibitors, and we have previously demonstrated the safety and activity of the novel water-soluble...
Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects (1998)
Ridge, S.A., Sludden, J., Brown, O., Robertson, L., Wei, X., Sapone, A., ...
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., ...
Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of...
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., ...
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for degradation of 5-fluorouracil (5-FU). DPD activity is highly variable in liver and peripheral mononuclear cells (PMNCs) and it...